Author

Svetomir N Markovic

Observed names: S. Markovic, Svetomir N. Markovic

Institutions: Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota)

Observed institutions: Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota)

ORCID: 0000-0002-9238-4325

Observed ORCID: 0000-0002-9238-4325

OpenAlex ID: A5075866861

Urinary CXCL-9 outperforms TNF-α for non-invasive diagnosis of immune checkpoint inhibitor–associated acute interstitial nephritis

2026 · Coraima Claudia Nava Chavez, Sheila Bermejo, et al. · Nephrology Dialysis Transplantation · 6

Toxicity attribution during enfortumab vedotin plus pembrolizumab therapy in urothelial carcinoma: a practical framework

2026 · Jabra Zarka, Daniel S Childs, et al. · The Oncologist

Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses

2026 · Joey C. Magno, Jitao Guo, et al. · Cancer Research

349P Immunoediting in the melanoma tumor microenvironment

2025 · K.E. Smith, C. Ward, et al. · Immuno-Oncology Technology

1518MO Rescuing cancer immunotherapy with plasma exchange in melanoma (the ReCIPE-M1 study)

2025 · J. Orme, H. Zhang, et al. · Annals of Oncology

MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas.

2011 · M. S. Block, V. Suman, et al. · Journal of Clinical Oncology

Works count: 6

Citation count: 6

H-index: 1

I10-index: